# Do GLP-1 Drugs Cause Suicidal Thoughts? What Regulators Found | Buy This GLP

What the FDA and EMA found about suicidal thoughts and GLP-1 medicines, and how to interpret reports of suspected side effects.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Safety

# Do GLP-1 Drugs Cause Suicidal Thoughts? What Regulators Found

The FDA found no increased risk in its review. A separate European study measured reporting patterns for medicines used in weight management.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Reporting odds versus tirzepatide · 1.0 · semaglutide · 2.69 · liraglutide · 2.54 · Weight-management reports only. Patient risk was not measured.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

The FDA’s review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines. In February 2026, U.S. labeling for Saxenda, Wegovy and Zepbound removed the warning after that review [\[3\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-3) [\[5\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-5) [\[6\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-6) [\[7\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-7).

## Key takeaways

-   The FDA reviewed 91 placebo-controlled trials involving 107,910 participants and analyzed insurance claims for more than 2.24 million adults with type 2 diabetes.
-   A European safety reporting study found differences in reporting odds among medicines used for weight management. Its data cannot estimate individual risk.
-   The European Medicines Agency’s 2024 review did not find evidence supporting a causal association for the five medicines it reviewed.

## What regulatory reviews found

The FDA’s trial review did not find increased suicidal ideation or behavior versus placebo. Its Sentinel insurance-claims analysis also found no increased risk of intentional self-harm among people with type 2 diabetes starting a GLP-1 medicine compared with those starting an SGLT2 inhibitor. The FDA continues to collect suspected side-effect reports through MedWatch [\[3\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-3).

In April 2024, the European Medicines Agency’s safety committee concluded that the available evidence did not support a causal link for dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide. The review did not include tirzepatide [\[4\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-4).

## What the European reports measured

Our guide to [FDA adverse event reports](https://buythisglp.com/research/what-the-adverse-event-database-says) explains why reports are useful for finding possible safety signals. EudraVigilance is a separate reporting system. In the European study, 42,941 reports met the selection criteria for type 2 diabetes, weight management or both [\[1\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-1).

In the weight-management-only subgroup, 225 reports described suspected suicide- or self-injury-related events: 37 naming liraglutide, 141 naming semaglutide and 47 naming tirzepatide. Compared with tirzepatide, the reporting odds ratio was 2.69 for semaglutide (95% confidence interval 1.91–3.83) and 2.54 for liraglutide (1.60–4.01) [\[1\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-1).

What reporting odds can tell us

The ratio compares the odds that a submitted report included the event of interest. The database does not count everyone who used each medicine. Differences in time on the market, publicity and poorly documented medical history can affect who appears in the reports [\[1\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-1).

## What patient records can show

A [Swedish national cohort](https://buythisglp.com/research/glp1-mental-illness-by-molecule) studied adults with depression or anxiety and looked at a broader measure of worsening mental illness. That measure included several outcomes beyond suicidal thoughts. The findings cannot establish that a GLP-1 medicine prevents self-harm [\[2\]](https://buythisglp.com/research/do-glp1-drugs-cause-suicidal-thoughts#ref-2).

If you develop new or worsening thoughts of suicide or self-harm, seek medical help right away. If you are in immediate danger, call your local emergency services.

## Frequently asked

What did the FDA find about suicidal thoughts and GLP-1 medicines?

The FDA found no increased risk of suicidal thoughts or behavior in its review. In February 2026 the warning was removed from U.S. labeling for Saxenda, Wegovy and Zepbound.

Did the European study count side effects in all people using these drugs?

It analyzed submitted reports. Among reports listing weight management alone, 225 described suspected suicide- or self-injury-related events. The study could not estimate the risk among people taking each medicine.

## Sources

1.  \[1\] Scavone C, et al. (2026). Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database Frontiers in Pharmacology. [PMID 42723821](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1882225/full)
2.  \[2\] Taipale H, et al. (2026). Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study The Lancet Psychiatry. [PMID 41862258](https://pubmed.ncbi.nlm.nih.gov/41862258/)
3.  \[3\] U.S. Food and Drug Administration (2026). FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications FDA Drug Safety Communication, January 13, 2026. [Source](https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp)
4.  \[4\] European Medicines Agency (2024). Meeting highlights from the Pharmacovigilance Risk Assessment Committee, April 8–11, 2024 European Medicines Agency. [Source](https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024)
5.  \[5\] Novo Nordisk (2026). Saxenda prescribing information, Recent Major Changes DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143)
6.  \[6\] Novo Nordisk (2026). Wegovy prescribing information, Recent Major Changes Drugs@FDA. [Source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf)
7.  \[7\] Eli Lilly and Company (2026). Zepbound prescribing information, Recent Major Changes DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)

## More in Safety

-   [
    
    Follow the prescription · Storefront → pharmacy → label
    
    ### How to Verify an Online Pharmacy for GLP-1 Medication
    
    ](https://buythisglp.com/research/how-to-verify-online-pharmacy-for-glp1)
-   [
    
    Warm delivery? Pause first. · Save the evidence. Call the pharmacy.
    
    ### Semaglutide Arrived Warm? What to Do Before Using It
    
    ](https://buythisglp.com/research/semaglutide-arrived-warm)
-   [
    
    503A pharmacy · 503B facility · Prescription · per patient · or office stock · CGMP · exempt · required · Oversight · state license · FDA, risk-based · Adverse events · no FDA duty · must report · FDA approval · no · no
    
    ### 503A vs 503B Pharmacy Rules for Compounded GLP-1s
    
    ](https://buythisglp.com/research/503a-vs-503b-pharmacy-compounded-glp1)
